PTC Inc.'s stock has seen various ups and downs based on its performance in the
biotech and
robotics sectors. While its role in
3D printing and additive manufacturing drew attention from hedge funds, there were also insider sales including CEO
James Heppelmann selling 35,000 shares and Director
Janice Chaffin selling over $700k in company stock. Despite internal selling, investments grew from
Swedbank AB and
SG Americas Securities LLC, while
Sumitomo Mitsui Trust Holdings Inc. lowered their stock holdings in PTC Inc. PTC's biggest drug 'Lives To Fight Another Day' caused stock to soar but also had moments of doubt with rejections, leading to market fluctuations.
Q3 earnings met estimates but full-year guidance underwhelmed despite Q1 exceeding expectations. Despite Its stock fluctuations, PTC has delivered solid returns of 115% over the past five years.
PTC Stocks News Analytics from Thu, 14 Dec 2023 08:00:00 GMT to Sun, 18 Aug 2024 15:50:10 GMT -
Rating 1
- Innovation 2
- Information 4
- Rumor -5
